Rhythm Pharmaceuticals (NASDAQ:RYTM) announced that the U.S. Food and Drug Administration has approved IMCIVREE ...
Prothena partners presented clinical data updates for prasinezumab for Parkinson’s and BMS-986446 for Alzheimer’s disease at AD/PD™ 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results